Actively including ulcerative colitis studies

Abbvie M16-067 / Inspire (anti IL23, Risankizumab):

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy

Abbvie M16-066 / Inspire:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

APD 334-301 (S1P1 receptor modulator, Etrasimod):

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled 52-Week Study of the Efficacy and Safety of Etrasimod in Subject with Moderately to Severe Active Ulcerative Colitis

Socrates (anti IL12/IL23, Stelara):

Stelara for chronic antibiotic refractory pouchitis: A Belgian open label multicenter pilot study

Prophetic (JAK inhibitor, Tofacitinib):

RP1907: Pharmacokinetics and pharmacodynamic biomarkers of tofacitinib therapy in patients with ulcerative colitis

Remidy (HMG-CoA-reductase inhibitor, Statins):

Drug repurposing - Statins as microbiota modulating agents in ulcerative colitis

Pfizer Tuscany 2 (anti TL1A, PF-06480605):

A phase 2B, multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy, safety, and pharmacokinetics of PF-06480605 in adult participants with moderate to severe ulcerative colitis

Verdict (anti α4β7-integrine, Vedolizumab):

VERDICT: In active ulcerative colitis, a randomized controlled trial for determination of the optimal treatment target

AMT-101-201 (fusion protein of IL10 and Cholix, AMT-101):

A combined phase 2/3 12-week, randomized, double-blind, placebo-controlled study investigating the efficacy of AMT-101 in subjects with chronic antibiotic-refractory pouchitis